BG104338A - Composition of lipid-reducing forms - Google Patents

Composition of lipid-reducing forms

Info

Publication number
BG104338A
BG104338A BG104338A BG10433800A BG104338A BG 104338 A BG104338 A BG 104338A BG 104338 A BG104338 A BG 104338A BG 10433800 A BG10433800 A BG 10433800A BG 104338 A BG104338 A BG 104338A
Authority
BG
Bulgaria
Prior art keywords
lipid
reducing
composition
smelt
time
Prior art date
Application number
BG104338A
Other languages
Bulgarian (bg)
English (en)
Inventor
Lieven Baert
Geert Verreck
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG104338A publication Critical patent/BG104338A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG104338A 1997-11-03 2000-04-14 Composition of lipid-reducing forms BG104338A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97203407 1997-11-03
PCT/EP1998/006998 WO1999022738A1 (en) 1997-11-03 1998-10-27 Compositions of lipid lowering agents

Publications (1)

Publication Number Publication Date
BG104338A true BG104338A (en) 2000-12-29

Family

ID=8228898

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104338A BG104338A (en) 1997-11-03 2000-04-14 Composition of lipid-reducing forms

Country Status (20)

Country Link
US (1) US6342245B1 (no)
EP (1) EP1028730B1 (no)
JP (1) JP2001521899A (no)
KR (2) KR20010023729A (no)
CN (1) CN1278175A (no)
AR (1) AR013739A1 (no)
AT (1) ATE216238T1 (no)
AU (1) AU746890B2 (no)
BG (1) BG104338A (no)
BR (1) BR9814109A (no)
CA (1) CA2307097A1 (no)
DE (1) DE69804994D1 (no)
EE (1) EE200000186A (no)
HU (1) HUP0004139A3 (no)
NO (1) NO20002279D0 (no)
NZ (1) NZ503413A (no)
PL (1) PL340305A1 (no)
SK (1) SK5972000A3 (no)
WO (1) WO1999022738A1 (no)
ZA (1) ZA989997B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
US20030059487A1 (en) * 2001-09-21 2003-03-27 Niazi Sarfaraz K. Composition and method for the treatment of hypercholesterolemia and hyperlipidemia in mammals
US6455557B1 (en) 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US8246986B2 (en) * 2003-09-26 2012-08-21 Alza Corporation Drug coating providing high drug loading
JP2007506775A (ja) * 2003-09-26 2007-03-22 アルザ・コーポレーシヨン 漸増する放出速度を表す制御放出製剤
WO2005030166A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Oros push-stick for controlled delivery of active agents
CA2540056C (en) * 2003-09-26 2015-03-24 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
CN101664411A (zh) 2003-11-14 2010-03-10 味之素株式会社 苯丙氨酸衍生物的固体分散体或固体分散体医药制剂
US20080280922A1 (en) * 2004-04-09 2008-11-13 Marc Alois Celine Maria Engelen Intermittent Dosing Regimen For Overweight and Obese Subjects
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
JP2008542255A (ja) * 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
EP1912626B1 (en) * 2005-08-08 2016-04-13 AbbVie Deutschland GmbH & Co KG Dosage forms with improved bioavailability
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2010143199A1 (en) 2009-06-11 2010-12-16 Suven Nishtaa Pharma Private Limited Solid lipid dispersion for aqueous solubility enhancement of poorly water soluble drugs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2155535T3 (es) * 1994-10-27 2001-05-16 Janssen Pharmaceutica Nv Inhibidores de sintesis de apoliproteina b.
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors

Also Published As

Publication number Publication date
CA2307097A1 (en) 1999-05-14
HUP0004139A2 (hu) 2002-02-28
KR20010023661A (ko) 2001-03-26
EE200000186A (et) 2001-04-16
AR013739A1 (es) 2001-01-10
NZ503413A (en) 2001-06-29
WO1999022738A1 (en) 1999-05-14
NO20002279L (no) 2000-04-28
KR20010023729A (ko) 2001-03-26
PL340305A1 (en) 2001-01-29
US6342245B1 (en) 2002-01-29
ZA989997B (en) 2000-05-02
SK5972000A3 (en) 2000-12-11
HUP0004139A3 (en) 2002-03-28
NO20002279D0 (no) 2000-04-28
EP1028730B1 (en) 2002-04-17
AU1157699A (en) 1999-05-24
CN1278175A (zh) 2000-12-27
AU746890B2 (en) 2002-05-02
BR9814109A (pt) 2000-10-03
EP1028730A1 (en) 2000-08-23
JP2001521899A (ja) 2001-11-13
DE69804994D1 (de) 2002-05-23
ATE216238T1 (de) 2002-05-15

Similar Documents

Publication Publication Date Title
EA200100024A1 (ru) Состав таблетки с делавирдином
NO20012529L (no) Dispersjoner av silylterminerte polymerer med höyt faststoffinnhold samt fremstilling og anvendelse derav
AU1339095A (en) Laxative compositions containing bulk fiber and dioctyl sulfosuccinate
BR9813154A (pt) Compósitos de fibra celulósica
BG104819A (en) Substituted indolealkanoic acids
IL126038A0 (en) Novel benzothiepines and derivatives thereof and pharmaceutical compositions comprising them
BG104276A (en) Composites of paper with polymer coating
CA2253797A1 (en) Luminous or fluorescent artificial stone composition
MX9707021A (es) Receptor de il-7.
NZ510254A (en) Novel composition and use
BR9713952A (pt) Composição de moldagem de polìmero, e, artigo de formação termoplástica.
BG102215A (en) Compounds and pharmaceutical compositions containing them
AU2002221702A1 (en) Pharmaceutical compositions
BR9814109A (pt) Composições de agentes de abaixamento de lipìdeos
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
BR9612809A (pt) Composição de plastissol, processo para preparação e uso da mesma, e, produto plastificado produzido a partir de uma composição de plastissol
AU1100897A (en) Stabilized antisun compositions
AU5493298A (en) Stabilized pharmaceutical compositions and process for the preparation thereof
AU8595791A (en) Galactomannan derivatives for coating or embedding medicinally active substances
EP1275379A3 (en) Basic granulate comprising (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
AU5277396A (en) Hydraulic cement
BG103412A (en) Stabilized pharmaceutical compositions based on chinupristine and dalfopristine and their preparation
BG101849A (en) Bicyclic tachyquinine antagonists, their preparation and use in pharmaceutical compositions
BG104022A (en) New beta-amino and beta-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor antagonists
DE69313634D1 (de) Elastosole sowie deren herstellung, verwendung und produkte